Acetaminophen Butalbital Caffeine

證據等級: L5

預測適應症: 0 個

Acetaminophen / Butalbital / Caffeine: Drug Repurposing Evaluation — No Prediction Available

One-Sentence Summary

Acetaminophen / Butalbital / Caffeine is a fixed-dose analgesic combination (commonly known as Fioricet) used for tension-type headaches and migraine relief. The TxGNN model returned no predicted new indications for this combination in the current pipeline run. Without a repurposing candidate, a full evidence-based evaluation cannot be completed — this report documents the data gaps and recommends remediation steps before proceeding.

Quick Overview

Item	Content
Original Indication	Not available in data pack
Predicted New Indication	None (TxGNN returned no candidates)
TxGNN Prediction Score	N/A
Evidence Level	L5 — No prediction returned
US Market Status	Not Marketed (per query result)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No repurposing prediction was returned by the TxGNN model for this combination. As a result, no mechanistic rationale or indication bridge can be constructed at this stage.

Currently, detailed mechanism of action data is not available. Based on known information, Acetaminophen / Butalbital / Caffeine is a three-component combination: acetaminophen provides analgesia and antipyresis, butalbital (a short-acting barbiturate) provides muscle relaxation and sedation, and caffeine acts as an adjuvant analgesic by enhancing CNS penetration and promoting cerebrovascular constriction. Its efficacy in tension-type headache has been established in clinical practice, and mechanistically the combination may be applicable to other pain or headache disorders — but this requires a formal TxGNN run with a correctly mapped DrugBank ID.

The most likely reason for the empty prediction is that the drugbank_id field is null, which prevents the knowledge graph from anchoring the drug in the TxGNN embedding space. Resolving this mapping gap is the critical prerequisite for any repurposing analysis.

Clinical Trial Evidence

Currently no related clinical trials registered.

(No predicted indication available — trial search requires a target indication.)

Literature Evidence

Currently no related literature available.

(No predicted indication available — literature search requires a target indication.)

US Market Information

No US FDA license records were returned for this drug combination under the queried name "ACETAMINOPHEN; BUTALBITAL; CAFFEINE".

Note: This combination is commercially available in the US under brand names such as Fioricet and Esgic. The zero-result query likely reflects a name formatting mismatch (semicolon-delimited multi-ingredient string vs. individual ingredient queries). It is recommended to requery using the individual active ingredients or the brand name.

Safety Considerations

Please refer to the package insert for safety information.

Key warnings, contraindications, and drug interaction data were not available in this Evidence Pack. Butalbital carries well-known risks of dependence and overuse headache; acetaminophen carries hepatotoxicity risk at high doses. A full safety review is required before any repurposing effort proceeds.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model returned no predicted indications for this combination, and the DrugBank ID is missing — without a knowledge graph anchor, no repurposing candidates can be generated or evaluated. All safety and regulatory data fields are also absent.

To proceed, the following is needed:

Resolve DrugBank mapping — Query DrugBank API for each individual active ingredient (acetaminophen DB00316, butalbital DB01083, caffeine DB00201) and assign the correct drugbank_id to re-run TxGNN prediction.
Fix regulatory query — Requery the US FDA database using ingredient-level searches or the brand name “Fioricet” to retrieve NDA records and approved indications.
Retrieve MOA data — Pull mechanism of action from DrugBank for each component to enable mechanistic plausibility scoring.
Retrieve safety data — Download the prescribing information to populate key warnings and contraindications, which are currently blocking the safety screen (DG001, severity: Blocking).
Re-run pipeline — After resolving the above gaps, re-execute the full TxGNN pipeline to obtain predicted indications and generate a complete evaluation report.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.